[Incretin-based co- and tri-agonists : Innovative polypharmacology for the treatment of obesity and diabetes].
The worldwide rise in overweight and obesity is paralleled by an increasing prevalence of type-2 diabetes. Apart from bariatric surgery, treatment options to decrease body weight are often underwhelming. Innovative pharmacological options are required to cope with the global "diabesity" pandemic. Particular novel pharmacological approaches are discussed, with a special focus on polyagonist-based pharmacotherapies. Articles on co- and tri-agonists for the treatment of obesity and diabetes are presented and discussed. Unimolecular peptides have been developed for the treatment of obesity and type-2 diabetes. These peptides activate the receptors of multiple hormones and bundle their positive effects in one single molecule. In preclinical studies, polyagonists targeting the receptors for glucagon-like peptide-1 (GLP-1), glucagon, or glucose-dependent insulinotropic peptide (GIP) were promising to reduce body weight and blood glucose. GLP-1-mediated delivery of the nuclear hormones estrogen or dexamethasone also yielded beneficial effects in preclinical studies of obesity. Polyagonists represent an innovative strategy for the development of novel pharmacotherapies to treat obesity and diabetes.